BioSpace News Archive

Letco Medical, LLC (Letco Med), is pleased to announce its three-year financial commitment of over $100,000 to fund the Alliance for Pharmacy Compounding (APC) nationwide advocacy campaign.

CEL-SCI Corporation (NYSE American: CVM) today announced that right after its previously scheduled Annual Shareholder Meeting, on July 1, 2021 at 10:00 am EDT, the Company will discuss its Phase 3 head and neck cancer trial results at the conclusion of the Annual Shareholder Meeting.

Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world’s most life-threatening diseases and public health threats, announced an advance purchase agreement with Gavi, the Vaccine Alliance, to provide up to 414 million doses of its protein-based COVID-19 vaccine candidate for procurement through the COVAX Facility.

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced the execution of a commercial supply agreement of Dynavax’s CpG 1018TM advanced adjuvant, for use in Clover’s protein-based COVID-19 vaccine candidate, SCB-2019.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases.

Solasia Pharma K.K. announced submission of a New Drug Application for its new anti-cancer drug darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare.

SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific.

HUTCHMED Limited announces the listing of its ordinary shares on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code “13” and the closing of its previously-announced primary offering of 104,000,000 new ordinary shares on the SEHK, which comprises an international offering of 91,000,000 Offer Shares and a Hong Kong public offering of 13,000,000 Offer Shares.

Azafaros B.V. today announced that Stefano Portolano, M.D., has joined Azafaros as Chief Executive Officer (CEO) and has concurrently been appointed to the Board of Directors of the company.

Remedent, Inc. announced the voluntary filing of a Form 15 with the United States Securities and Exchange Commission to terminate the registration of its common stock under Section 12 Securities Exchange Act of 1934, as amended and suspend its SEC reporting obligations under Section 15 of the Exchange Act.